Astellas Pharma Stock News
¥2,397.50
1.63%
Tokyo, Sep 25, 03:15 pm JST.
Closed.
Industry
Astellas Pharma Stock News
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung cancer (NSCLC) whose disease has progresse...
– Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our commitment to patient access, affordability and innovation, while reinforcing Astellas' longstanding commit...
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
